# US 2023/0405061 A1 · Combination product for prophylaxis and treatment of irritable bowel syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0405061 A1
- Document ID: US20230405061A1
- Status: Published application
- Kind: A1
- Application number: 18/352,485
- Filed: 2023-07-14
- Published: 2023-12-21
- Earliest claimed: 2018-01-29
- Assignees: PrecisionBiotics Group Limited
- Applicants: Precisionbiotics Group Limited
- Inventors: Barry KIELY; Eileen Frances MURPHY; David GROEGER
- Web page: https://patentgrep.com/patent/US20230405061A1

## CPC

- A61K 35/745: Bifidobacteria
- A23C 9/1234: {characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.}
- A23K 10/18: of live microorganisms
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A23V 2400/11: Lactobacillus
- A23V 2400/51: Bifidobacterium
- A23V 2400/533: Longum
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/48: Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23C: DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF (preservation thereof A23B11/00)
- A23K: FODDER
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

A combination product comprising an isolated strain of Bifidobacterium NCIMB 41003 and another strain which does not adversely interact with Bifidobacterium NCIMB 41003 improves gastrointestinal symptoms associated with IBS and improves one or more of mood, stress, anxiety, sleep quality and depression associated with IBS.

## Claims

### Claim at position 1

1-40. (canceled)

### Claim 41

A formulation for administration to a subject, the formulation comprising an isolated strain of Bifidobacterium deposited under accession number NCIMB 41676, an isolated strain of Bifidobacterium deposited under accession number NCIMB 41003, and an ingestible carrier.

### Claim 42 (depends on 41)

The formulation of claim 41, wherein the ingestible carrier is a pharmaceutically acceptable carrier chosen from a capsule, a tablet, or a powder.

### Claim 43 (depends on 41)

The formulation of claim 41, wherein the ingestible carrier is a food product chosen from acidified milk, a yoghurt, a frozen food, a gum, a candy, a milk powder, a milk concentrate, a cheese spread, a nutritional composition, a nutritional supplement, a cereal-bar, a dressing or a beverage.

### Claim 44 (depends on 41)

The formulation of claim 41, wherein the formulation is an infant food.

### Claim 45 (depends on 41)

The formulation of claim 41, wherein the formulation is in the form of a bacterial broth.

### Claim 46 (depends on 41)

The formulation of claim 41, wherein the formulation is in the form of a freeze-dried powder.

### Claim 47 (depends on 41)

The formulation of claim 41, wherein the formulation is in the form of a fermented food product.

### Claim 48 (depends on 41)

The formulation of claim 41, wherein at least one of the Bifidobacterium strains is in the form of viable cells.

### Claim 49 (depends on 41)

The formulation of claim 41, wherein at least one of the Bifidobacterium strains is in the form of non-viable cells.

### Claim 50 (depends on 41)

The formulation of claim 41, wherein one or both of the Bifidobacterium strains is present in the formulation in an amount of more than 106 cfu.

### Claim 51 (depends on 41)

The formulation of claim 41, wherein one or both of the Bifidobacterium strains is present in the formulation in an amount of from 108 cfu to 109 cfu.

### Claim 52 (depends on 41)

The formulation of claim 41, further comprising a prebiotic material.

### Claim 53 (depends on 41)

The formulation of claim 41, further comprising a protein, a peptide, or both a protein and a peptide.

### Claim 54 (depends on 41)

The formulation of claim 41, further comprising a lipid, a carbohydrate, a vitamin, a mineral, a trace element, or a combination thereof.

### Claim 55

A formulation for oral administration to a subject, the formulation comprising an isolated strain of Bifidobacterium deposited under accession number NCIMB 41676, an isolated strain of Bifidobacterium deposited under accession number NCIMB 41003, and an ingestible carrier, wherein the formulation is in the form of a capsule, a tablet, or a powder.

### Claim 56 (depends on 55)

The formulation of claim 55, wherein one or both of the Bifidobacterium strains is in the form of a freeze dried powder.

### Claim 57 (depends on 55)

The formulation of claim 55, wherein one or both of the Bifidobacterium strains is present in the formulation in an amount of more than 106 cfu.

### Claim 58

A formulation for oral administration to a subject, the formulation comprising a powder that comprises 108 cfu to 1010 cfu of an isolated strain of Bifidobacterium deposited under accession number NCIMB 41676 and 108 cfu to 1010 cfu of an isolated strain of Bifidobacterium deposited under accession number NCIMB 41003, the formulation further comprising an ingestible carrier.

### Claim 59 (depends on 58)

The formulation of claim 58, wherein the ingestible carrier is a food product chosen from acidified milk, a yoghurt, a frozen food, a gum, a candy, a milk powder, a milk concentrate, a cheese spread, a nutritional composition, a nutritional supplement, a cereal-bar, a dressing or a beverage.

### Claim 60 (depends on 58)

The formulation of claim 58, further comprising a lipid, a carbohydrate, a vitamin, a mineral, a trace element, or a combination thereof.
